Study of Lifestyle Modification in HIV Lipodystrophy
The Effects of a Lifestyle Modification Program (REACH) in Patients With HIV and Metabolic Syndrome
調査の概要
詳細な説明
This study is designed as a randomized, case-control study of 80 subjects (N=80). Forty subjects will be randomized to the observation group and 40 to the intervention (REACH) group.
After two initial screening visits with medical and nutrition staff for informed consent, determination of eligibility, and evaluation of a 7-day food record, qualifying patients will be seen for a baseline visit. A nutrition questionnaire and bioimpedance analysis (BIA) testing will be done at the first screening visit, and sub-maximal stress testing and other tests with physical therapy will be done at the second screening visit.
At baseline, patients will have an interval history and physical exam, lipodystrophy evaluation by the investigator (objective) and patient (subjective) report, blood tests and body composition.
Nearly identical visits to that at baseline, with the addition of the sub-maximal stress test, and other physical therapy testing, will be repeated at 6 and 12 months. Carotid ultrasound will be repeated at the 6 and 12 month visits. There will also be a short visit at 3 and 9 months to obtain an interval history and physical exam, safety labs, and a 7-day food record for an Intake Report.
At baseline, patients will be randomized to either the observation group or the lifestyle intervention, known as "Reach for Energy, Activity, and Cardiovascular Health" (REACH). Randomization will be stratified for gender and fasting glucose < or >= 110 mg/dL.
Those randomized to observation will receive a one time counseling session with nutrition staff at the baseline visit and monthly, unscripted phone calls from the investigator/co-investigator, and come in for regular study visits at 3, 6, 9, and 12 months, as described above.
Those randomized to REACH will attend one-on-one counseling sessions with a trained dietitian covering the "core-curriculum" that is modeled after the Diabetes Prevention Program (DPP) study 16 week core curriculum intervention.
研究の種類
入学 (予想される)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02114
- Mass General Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age greater than or equal to 18 and less than or equal to 65 years of age
- HIV+
- Ability and motivation to modify behavior and make lifestyle changes
3 out of 5 of the following:
- Waist circumference greater than 102 cm (40 in) in men and 88 cm (35 in) in women;
- Triglycerides greater than or equal to 150 mg/dL or current anti-lipolytic drug treatment;
- High-density lipoprotein (HDL) less than 40 mg/dL in men and 50 mg/dL in women;
- Blood pressure greater than or equal to 130/85 mmHg or current antihypertensive drug treatment;
- Fasting glucose greater than or equal to 110 mg/dL.
Exclusion Criteria:
- History of unstable angina, aortic stenosis, uncontrolled hypertension, severe neuropathy, arthritis or other contraindication to exercise
- Requiring pharmacological glucocorticoid therapy (> 7.5mg Prednisone or its equivalent/day)
- Androgen, growth hormone or Megace within 3 months of study initiation. Subjects on a standard dose of testosterone for documented hypogonadism for > 3 months will be allowed to enter the study.
- New anti-retroviral therapy within 1 month of study initiation
- SGPT > 5X normal and/or clinically significant liver disease
- Creatinine > 2.0 mg/dL and/or clinically significant renal disease
- Hemoglobin (Hgb) < 9 g/dL
- Current drug or alcohol abuse
- History of diabetes mellitus or fasting glucose of greater than or equal to 126 mg/dL
- Current therapy with insulin or other diabetic agent
- Pregnant or actively seeking pregnancy
- Breastfeeding
- Inability to comply with intervention due to lack of motivation, time, social, and/or psychological support
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
プラセボコンパレーター:コントロール
|
|
アクティブコンパレータ:Lifestyle Modification
Goals derived from the AACE and NCEP-ATP III guidelines and the Diabetes Prevention Program are as follows: <35% calories from fat, < 7% calories from saturated fat, up to 10% calories from polyunsaturated fat, reduction of trans fatty acid intake, up to 20% calories from monounsaturated fat, and 25-35g of fiber per day. 3 hrs of physical activity/week at moderate intensity, >10,000 steps in daily activity, measured by pedometer.
The curriculum is modeled after the Diabetes Prevention Program.
Subjects will complete lifestyle sessions in the offices of the Program in Nutritional Metabolism or in the Clinical Research Center at MGH with protocol study staff trained to implement the curriculum.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
---|
WHR
|
二次結果の測定
結果測定 |
---|
血圧
|
CRP
|
総コレステロール
|
HDL
|
LDL
|
triglyceride cholesterol levels
|
cardiac enzymes
|
t-PA
|
PAI
|
insulin and glucose metabolism
|
協力者と研究者
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 49302-P1 (completed)
- R01DK049302 (米国 NIH グラント/契約)
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
ライフスタイルの修正の臨床試験
-
Oxford Biomedical Technologies, Inc.募集
-
Universiti Sultan Zainal Abidin募集
-
University of Alabama at Birmingham積極的、募集していない